(211)At-labeled agents for alpha-immunotherapy: On the in vivo stability of astatine-agent bonds

Eur J Med Chem. 2016 Jun 30:116:156-164. doi: 10.1016/j.ejmech.2016.03.082. Epub 2016 Mar 29.

Abstract

The application of (211)At to targeted cancer therapy is currently hindered by the rapid deastatination that occurs in vivo. As the deastatination mechanism is unknown, we tackled this issue from the viewpoint of the intrinsic properties of At-involving chemical bonds. An apparent correlation has been evidenced between in vivo stability of (211)At-labeled compounds and the At-R (R = C, B) bond enthalpies obtained from relativistic quantum mechanical calculations. Furthermore, we highlight important differences in the nature of the At-C and At-B bonds of interest, e.g. the opposite signs of the effective astatine charges, which implies different stabilities with respect to the biological medium. Beyond their practical use for rationalizing the labeling protocols used for (211)At, the proposed computational approach can readily be used to investigate bioactive molecules labeled with other heavy radionuclides.

Keywords: Astatine; Bond enthalpy; Density functional theory; In vivo stability; Targeted radionuclide therapy.

MeSH terms

  • Astatine / chemistry*
  • Astatine / therapeutic use*
  • Drug Stability
  • Immunotherapy / methods*
  • Isotope Labeling
  • Models, Molecular
  • Molecular Conformation

Substances

  • Astatine